800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF (LEVEL)

view all Clinical Trials

Overview

This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).

Clinical Trial Information

Protocol

IRB#: 31458

Phase

3

Condition(s)

Pulmonary Hypertension (PH)

Investigator

Eman Hamad, MD

Coordinator

Yaminah Carter
215-707-3898

Visit clinicaltrials.gov for full description.

Contact

For more information about this trial or to inquire about eligibility, call 215-707-3898.

Full Title

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF)

Related Clinical Trials

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension (ARTISAN)

IRB#: 30634
  • Conditions: Pulmonary Arterial Hypertension (PAH)
  • Investigator: Ahmed Sadek, MD
  • Coordinator: Liz Westburg (215-707-3898)
View Details

Assessment of Combined CCM and ICD Device in HFrEF (INTEGRA-D)

IRB#: 30636
  • Conditions: Heart Failure
  • Investigator: Edmond Cronin, MD, CCDS, FHRS
  • Coordinator: Liz Westburg (215-707-3898)
View Details

Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer)

IRB#: 29417
  • Conditions: Heart Failure
  • Investigator: Eman Hamad, MD
  • Coordinator: Kriti Rawat (215-707-3898)
View Details